Global Insulin Biosimilars Market Growth 2024-2030

Publication ID:

LPI11244640

Publication Date:

December 2, 2024

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Insulin Biosimilars market size was valued at US$ 1447.8 million in 2023. With growing demand in downstream market, the Insulin Biosimilars is forecast to a readjusted size of US$ 1858.4 million by 2030 with a CAGR of 3.6% during review period.
The research report highlights the growth potential of the global Insulin Biosimilars market. Insulin Biosimilars are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Insulin Biosimilars. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Insulin Biosimilars market.
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Insulin Biosimilars market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Insulin Biosimilars market. It may include historical data, market segmentation by Type (e.g., Rapid-Acting Biosimilars, Long-Acting Biosimilars), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Insulin Biosimilars market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Insulin Biosimilars market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Insulin Biosimilars industry. This include advancements in Insulin Biosimilars technology, Insulin Biosimilars new entrants, Insulin Biosimilars new investment, and other innovations that are shaping the future of Insulin Biosimilars.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Insulin Biosimilars market. It includes factors influencing customer ' purchasing decisions, preferences for Insulin Biosimilars product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Insulin Biosimilars market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Insulin Biosimilars market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Insulin Biosimilars market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Insulin Biosimilars industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Insulin Biosimilars market.
Market Segmentation:
Insulin Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Segmentation by application
Type I Diabetes
Type II Diabetes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Insulin Biosimilars market?
What factors are driving Insulin Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin Biosimilars market opportunities vary by end market size?
How does Insulin Biosimilars break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Insulin Biosimilars Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Insulin Biosimilars by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Insulin Biosimilars by Country/Region, 2019, 2023 & 2030
2.2 Insulin Biosimilars Segment by Type
2.2.1 Rapid-Acting Biosimilars
2.2.2 Long-Acting Biosimilars
2.2.3 Premixed Biosimilars
2.3 Insulin Biosimilars Sales by Type
2.3.1 Global Insulin Biosimilars Sales Market Share by Type (2019-2024)
2.3.2 Global Insulin Biosimilars Revenue and Market Share by Type (2019-2024)
2.3.3 Global Insulin Biosimilars Sale Price by Type (2019-2024)
2.4 Insulin Biosimilars Segment by Application
2.4.1 Type I Diabetes
2.4.2 Type II Diabetes
2.5 Insulin Biosimilars Sales by Application
2.5.1 Global Insulin Biosimilars Sale Market Share by Application (2019-2024)
2.5.2 Global Insulin Biosimilars Revenue and Market Share by Application (2019-2024)
2.5.3 Global Insulin Biosimilars Sale Price by Application (2019-2024)
3 Global Insulin Biosimilars by Company
3.1 Global Insulin Biosimilars Breakdown Data by Company
3.1.1 Global Insulin Biosimilars Annual Sales by Company (2019-2024)
3.1.2 Global Insulin Biosimilars Sales Market Share by Company (2019-2024)
3.2 Global Insulin Biosimilars Annual Revenue by Company (2019-2024)
3.2.1 Global Insulin Biosimilars Revenue by Company (2019-2024)
3.2.2 Global Insulin Biosimilars Revenue Market Share by Company (2019-2024)
3.3 Global Insulin Biosimilars Sale Price by Company
3.4 Key Manufacturers Insulin Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Insulin Biosimilars Product Location Distribution
3.4.2 Players Insulin Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Insulin Biosimilars by Geographic Region
4.1 World Historic Insulin Biosimilars Market Size by Geographic Region (2019-2024)
4.1.1 Global Insulin Biosimilars Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Insulin Biosimilars Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Insulin Biosimilars Market Size by Country/Region (2019-2024)
4.2.1 Global Insulin Biosimilars Annual Sales by Country/Region (2019-2024)
4.2.2 Global Insulin Biosimilars Annual Revenue by Country/Region (2019-2024)
4.3 Americas Insulin Biosimilars Sales Growth
4.4 APAC Insulin Biosimilars Sales Growth
4.5 Europe Insulin Biosimilars Sales Growth
4.6 Middle East & Africa Insulin Biosimilars Sales Growth
5 Americas
5.1 Americas Insulin Biosimilars Sales by Country
5.1.1 Americas Insulin Biosimilars Sales by Country (2019-2024)
5.1.2 Americas Insulin Biosimilars Revenue by Country (2019-2024)
5.2 Americas Insulin Biosimilars Sales by Type
5.3 Americas Insulin Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Insulin Biosimilars Sales by Region
6.1.1 APAC Insulin Biosimilars Sales by Region (2019-2024)
6.1.2 APAC Insulin Biosimilars Revenue by Region (2019-2024)
6.2 APAC Insulin Biosimilars Sales by Type
6.3 APAC Insulin Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Insulin Biosimilars by Country
7.1.1 Europe Insulin Biosimilars Sales by Country (2019-2024)
7.1.2 Europe Insulin Biosimilars Revenue by Country (2019-2024)
7.2 Europe Insulin Biosimilars Sales by Type
7.3 Europe Insulin Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Insulin Biosimilars by Country
8.1.1 Middle East & Africa Insulin Biosimilars Sales by Country (2019-2024)
8.1.2 Middle East & Africa Insulin Biosimilars Revenue by Country (2019-2024)
8.2 Middle East & Africa Insulin Biosimilars Sales by Type
8.3 Middle East & Africa Insulin Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Insulin Biosimilars
10.3 Manufacturing Process Analysis of Insulin Biosimilars
10.4 Industry Chain Structure of Insulin Biosimilars
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Insulin Biosimilars Distributors
11.3 Insulin Biosimilars Customer
12 World Forecast Review for Insulin Biosimilars by Geographic Region
12.1 Global Insulin Biosimilars Market Size Forecast by Region
12.1.1 Global Insulin Biosimilars Forecast by Region (2025-2030)
12.1.2 Global Insulin Biosimilars Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Insulin Biosimilars Forecast by Type
12.7 Global Insulin Biosimilars Forecast by Application
13 Key Players Analysis
13.1 Sanofi S.A.
13.1.1 Sanofi S.A. Company Information
13.1.2 Sanofi S.A. Insulin Biosimilars Product Portfolios and Specifications
13.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Sanofi S.A. Main Business Overview
13.1.5 Sanofi S.A. Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Insulin Biosimilars Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Eli Lilly & Co.
13.3.1 Eli Lilly & Co. Company Information
13.3.2 Eli Lilly & Co. Insulin Biosimilars Product Portfolios and Specifications
13.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Eli Lilly & Co. Main Business Overview
13.3.5 Eli Lilly & Co. Latest Developments
13.4 Novo Nordisk A/S
13.4.1 Novo Nordisk A/S Company Information
13.4.2 Novo Nordisk A/S Insulin Biosimilars Product Portfolios and Specifications
13.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novo Nordisk A/S Main Business Overview
13.4.5 Novo Nordisk A/S Latest Developments
13.5 Biocon
13.5.1 Biocon Company Information
13.5.2 Biocon Insulin Biosimilars Product Portfolios and Specifications
13.5.3 Biocon Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Biocon Main Business Overview
13.5.5 Biocon Latest Developments
13.6 Geropharm
13.6.1 Geropharm Company Information
13.6.2 Geropharm Insulin Biosimilars Product Portfolios and Specifications
13.6.3 Geropharm Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Geropharm Main Business Overview
13.6.5 Geropharm Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Insulin Biosimilars Product Portfolios and Specifications
13.7.3 Wockhardt Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 Gan&Lee Pharmaceuticals
13.8.1 Gan&Lee Pharmaceuticals Company Information
13.8.2 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolios and Specifications
13.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Gan&Lee Pharmaceuticals Main Business Overview
13.8.5 Gan&Lee Pharmaceuticals Latest Developments
13.9 The United Laboratories International
13.9.1 The United Laboratories International Company Information
13.9.2 The United Laboratories International Insulin Biosimilars Product Portfolios and Specifications
13.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 The United Laboratories International Main Business Overview
13.9.5 The United Laboratories International Latest Developments
13.10 Tonghua Dongbao Pharmaceutical
13.10.1 Tonghua Dongbao Pharmaceutical Company Information
13.10.2 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolios and Specifications
13.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂